| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5280524
Max Phase: Preclinical
Molecular Formula: C18H17ClFN3S
Molecular Weight: 361.87
Associated Items:
Representations
Canonical SMILES: CCNC(=S)N1N=C(c2ccc(Cl)cc2)CC1c1ccc(F)cc1
Standard InChI: InChI=1S/C18H17ClFN3S/c1-2-21-18(24)23-17(13-5-9-15(20)10-6-13)11-16(22-23)12-3-7-14(19)8-4-12/h3-10,17H,2,11H2,1H3,(H,21,24)
Standard InChI Key: JYSVAOLIDNHENN-UHFFFAOYSA-N
Associated Targets(Human)
Monoamine oxidase A 11911 Activities
Monoamine oxidase B 8835 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 361.87 | Molecular Weight (Monoisotopic): 361.0816 | AlogP: 4.52 | #Rotatable Bonds: 3 |
| Polar Surface Area: 27.63 | Molecular Species: NEUTRAL | HBA: 2 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 3 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 11.07 | CX Basic pKa: 1.06 | CX LogP: 4.78 | CX LogD: 4.78 |
| Aromatic Rings: 2 | Heavy Atoms: 24 | QED Weighted: 0.81 | Np Likeness Score: -1.79 |
References
| 1. Nehra B, Rulhania S, Jaswal S, Kumar B, Singh G, Monga V.. (2020) Recent advancements in the development of bioactive pyrazoline derivatives., 205 [PMID:32795767] [10.1016/j.ejmech.2020.112666] |
Source
Source(1):